Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Natco Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was ₹18,526 Mil.
Natco Pharma's quarterly Total Liabilities
declined
from Sep. 2025 (₹17,759.00 Mil) to Dec. 2025 (₹0.00 Mil) but then
increased
from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹18,526.00 Mil).
Natco Pharma's annual Total Liabilities
declined
from Mar. 2024 (₹10,532.00 Mil) to Mar. 2025 (₹10,185.00 Mil) but then
increased
from Mar. 2025 (₹10,185.00 Mil) to Mar. 2026 (₹18,526.00 Mil).
Natco Pharma Total Liabilities Related Terms
Natco Pharma Total Liabilities Historical Data
* Premium members only.
The historical data trend for Natco Pharma's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Natco Pharma's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of ₹18,526 Mil mean?
Natco Pharma (NSE:NATCOPHARM) has a Total Liabilities of ₹18,526 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Natco Pharma and its competitors.
Is Natco Pharma's Total Liabilities too high?
Natco Pharma's current Total Liabilities is ₹18,526 Mil. Overall, Natco Pharma has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Total Liabilities compare to ZTS and UTHR?
Natco Pharma's Total Liabilities of ₹18,526 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Natco Pharma and its competitors. Natco Pharma's current Total Liabilities is ₹18,526 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹925.86, compared to a current price of ₹918.55 — trading 0.8% below its estimated fair value. The current Total Liabilities is ₹18,526 Mil. Natco Pharma's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current Total Liabilities is ₹18,526 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued.
The current stock price of ₹918.55 is trading 0.8% below its estimated GF Value™ of ₹925.86.
GuruFocus considers Natco Pharma to be Fairly Valued.
Key valuation signals for NSE:NATCOPHARM:
Total Liabilities: ₹18,526 Mil
GF Value™: ₹925.86 vs. price of ₹918.55 (0.8% below fair value)
No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
88GF Score
Get the complete analysis for NSE:NATCOPHARM
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NATCOPHARM has been successfully added to your 
